CK2 α 2 Human Active

CK2 Œ± 2 Human Active_x000D_ Catalog number: B2014092_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 10 µg_x000D_ Molecular Weight or Concentration: ~64 kDa_x000D_ Supplied as: Solution_x000D_ Applications: molecular tool for various biochemical applications_x000D_ Storage: -20¬∞C_x000D_ Keywords: CK2A2, CKII-Œ± 2, CSNK2A2_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MŒ©-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Zeng KW, Wang JK, Wang LC, Guo Q, Liu TT, Wang FJ, Feng N, Zhang XW, Liao LX, Zhao MM, Liu D, Jiang Y, Tu P. Small molecule induces mitochondrial fusion for neuroprotection via targeting CK2 without affecting its conventional kinase activity Signal Transduct Target Ther. 2021 Feb 19;6(1):71._x000D_ 2: Jeong E, Martina JA, Contreras PS, Lee J, Puertollano R. The FACT complex facilitates expression of lysosomal and antioxidant genes through binding to TFEB and TFE3 Autophagy. 2022 Oct;18(10):2333-2349._x000D_ 3: Chen JH, Zhang P, Chen WD, Li DD, Wu XQ, Deng R, Jiao L, Li X, Ji J, Feng GK, Zeng YX, Jiang JW, Zhu XF. ATM-mediated PTEN phosphorylation promotes PTEN nuclear translocation and autophagy in response to DNA-damaging agents in cancer cells Autophagy. 2015;11(2):239-52._x000D_ 4: Shrimali D, Shanmugam MK, Kumar AP, Zhang J, Tan BK, Ahn KS, Sethi G. Targeted abrogation of diverse signal transduction cascades by emodin for the treatment of inflammatory disorders and cancer Cancer Lett. 2013 Dec 1;341(2):139-49._x000D_ 5: Lolli G, Naressi D, Sarno S, Battistutta R. Characterization of the oligomeric states of the CK2 (2)_(2) holoenzyme in solution Biochem J. 2017 Jul 6;474(14):2405-2416._x000D_ 6: Hales EC, Taub JW, Matherly LH. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of _-secretase inhibitor resistant T-cell acute lymphoblastic leukemia Cell Signal. 2014 Jan;26(1):149-61._x000D_ 7: Howard JF Jr, Nowak RJ, Wolfe GI, Freimer ML, Vu TH, Hinton JL, Benatar M, Duda PW, MacDougall JE, Farzaneh-Far R, Kaminski HJ; Zilucoplan MG Study Group; Barohn R, Dimachkie M, Pasnoor M, Farmakidis C, Liu T, Colgan S, Benatar MG, Bertorini T, Pillai R, Henegar R, Bromberg M, Gibson S, Janecki T, Freimer M, Elsheikh B, Matisak P, Genge A, Guidon A, David W, Habib AA, Mathew V, Mozaffar T, Hinton JL, Hewitt W, Barnett D, Sullivan P, Ho D, Howard JF Jr, Traub RE, Chopra M, Kaminski HJ, Aly R, Bayat E, Abu-Rub M, Khan S, Lange D, Holzberg S, Khatri B, Lindman E, Olapo T, Sershon LM, Lisak RP, Bernitsas E, Jia K, Malik R, Lewis-Collins TD, Nicolle M, Nowak RJ, Sharma A, Roy B, Nye J, Pulley M, Berger A, Shabbir Y, Sachdev A, Patterson K, Siddiqi Z, Sivak M, Bratton J, Small G, Kohli A, Fetter M, Vu T, Lam L, Harvey B, Wolfe GI, Silvestri N, Patrick K, Zakalik K, Duda PW, MacDougall J, Farzaneh-Far R, Pontius A, Hoarty M. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial JAMA Neurol. 2020 May 1;77(5):582-592._x000D_ 8: Pinna LA, Meggio F. Protein kinase CK2 ("casein kinase-2") and its implication in cell division and proliferation Prog Cell Cycle Res. 1997;3:77-97._x000D_ 9: H_bner GM, Larsen JN, Guerra B, Niefind K, Vrecl M, Issinger OG. Evidence for aggregation of protein kinase CK2 in the cell: a novel strategy for studying CK2 holoenzyme interaction by BRET(2) Mol Cell Biochem. 2014 Dec;397(1-2):285-93._x000D_ 10: Husain K, Williamson TT, Nelson N, Ghansah T. Protein kinase 2 (CK2): a potential regulator of immune cell development and function in cancer Immunol Med. 2021 Sep;44(3):159-174. _x000D_ _x000D_ Products Related to CK2 Œ± 2 Human Active can be found at Proteins

Catalog Number: B2014092 (10 µg)

0.15

2

0.5